AstraZeneca has successfully wrapped a small proof-of-concept study to help demonstrate how two immunotherapy drugs will likely work better than one. The pharma giant is reporting that a combination of the PD-L1 drug durvalumab combined with the CTLA-4 treatment tremelimumab achieved an objective tumor response rate of 23% for metastatic non-small cell lung cancer patients.
China once again aided AstraZeneca, with the full-year sales up 15%, the same pace as Latin America, and up 10% on the fourth quarter.
AstraZeneca recently plunked down $575 million to get from Takeda global rights to the chronic obstructive pulmonary disease treatment Daxas. It was the kind of deal that currently intrigues CEO Pascal Soriot, something that will immediately pay off and which falls into one of the three areas around which he is trying to rebuild the company.
AstraZeneca is suffering from a new round of patent losses, and that suffering will only worsen. Already hurting from generic competition to its former top-seller, Nexium, the London-based company will fall off another patent cliff this year--Crestor--and faces still another in Seroquel XR next year.
AstraZeneca has outlined how it is using the white-hot CRISPR genome editing technology to put its repositories of sequencing data to work in its R&D programs. The initiative is one of the many ways in which AstraZeneca is applying the technology at its drug discovery and development units.
As it prepares to be subsumed in the $160 billion merger deal with Pfizer, Ireland's Allergan is not backing away from making deals. The company unveiled a three-way pact with AstraZeneca this morning to develop a new antibiotic with the help of a U.S. government agency.
A clutch of big-name drugmakers have teamed up to digitize the drug formulation development process. AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline and Pfizer are involved with the initiative, which is aiming to develop digital tools and processes that spot nonviable molecules earlier in development.
Three of the U.K.'s leading universities are joining hands with three of the world's biggest pharma giants to create a new translational medicine group aimed at spinning out new therapies into the global pipeline.
AstraZeneca CEO Pascal Soriot summarizes his accomplishments at the U.K.-based pharma giant in two words--Lynparza and Tagrisso.
India's patent office came down on the side of pharma giant AstraZeneca when it rejected a compulsory license application filed by Hyderabad-based Lee Pharma.